²é¿´: 5078  |  »Ø¸´: 87
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

chen36904311

½ð³æ (СÓÐÃûÆø)


ÒÑÁìÍê
°ÄÃÅ´óѧ³ÂнÌÊÚ¿ÎÌâ×é2019ÄêÕÐÊÕ˶ʿÑо¿Éú¡¢²©Ê¿Ñо¿Éú¡¢Ñо¿ÖúÀí¼°²©Ê¿ºóÑо¿Ô±
ÁìÈ¡ºì°ü (Сľ³æÊÖ»úappרÊôºì°ü)

ɨһɨ£¬ÏÂÔØСľ³æ¿Í»§¶Ë

°ÄÃÅ´óѧ³ÂнÌÊÚ¿ÎÌâ×é2019ÄêÕÐÊÕ˶ʿ£¨º¬ÍÆÃ⣩Ñо¿Éú¡¢²©Ê¿£¨º¬Ö±²©£©Ñо¿Éú¡¢Ñо¿ÖúÀí¼°²©Ê¿ºóÑо¿Ô±

°ÄÃÅ´óѧ³ÂнÌÊÚ (Professor Xin Chen) ¿ÎÌâ×é2019ÄêÕÐÊÕ˶ʿ£¨º¬ÍÆÃ⣩Ñо¿Éú£¬²©Ê¿£¨º¬Ö±²©£©Ñо¿Éú, ²©Ê¿ºóÑо¿Ô±

ÒªÇó£º ¾ßÓÐÉúÎï¡¢Ò½Ò©Ïà¹Øѧ¿Æѧ룬ÊìϤ¶¯ÎïʵÑ鼰ϸ°û²Ù×÷¼¼Êõ£¬¾ßÓÐÃâÒßѧ±³¾°ÓÅÏÈ¡£¶Ô¿ÆѧÑо¿ÓÐÇ¿ÁÒÐËȤ£¬ÎªÈ˳ÏÐÅ£¬¹¤×÷ÇÚ·Ü£¬ÉÆÓÚ¹µÍ¨£¬ÓжÀÁ¢Ë¼¿¼¼°¹¤×÷ÄÜÁ¦£¬²©Ê¿ºó¼°²©Ê¿ÉúÉêÇëÕßÐèÓз¢±íSCIÎÄÕ¾­Ñ飬ӢÎÄˮƽÐèÒª·ûºÏ°ÄÃÅ´óѧҪÇó¡£

Ñо¿·½Ïò£º ÃâÒßµ÷½Ú»úÖƼ°ÃâÒßÒ©Àí

°ÄÃÅ´óѧ2019/2020ѧÄêÕÐÊÕÍƼöÃâÊÔ˶ʿ¡¢²©Ê¿£¨Ö±½Ó¶Á²©£©Ñо¿Éú
https://www.umac.mo/grs/cn/admissions.php

°Ä´ó²©Ê¿ÉúÖúѧ½ð
²©Ê¿ÉúÖúѧ½ðµÄ×ÊÖúÀ´×Ô´óѧ¾­·Ñ»òµ¼Ê¦µÄ¿ÆÑо­·Ñ¡£»ñµÃ²©Ê¿ÉúÖúѧ½ð֮ѧÉú¿É»ñÿÔ°ÄÃűÒ12,500Ôª(×î¸ß¿É´ï°ÄÃűÒ14,000Ôª)µÄ½òÌù¡£
°Ä´ó²©Ê¿ÉúÖúѧ½ðÏêÇéhttps://www.umac.mo/grs/cn/admissions_phd_assistantship.php

°Ä´ó婽­²©Ê¿Éú½±Ñ§½ð
»ñ°ä´Ë½±Ñ§½ðÖ®²©Ê¿Ñо¿Éú»ñÿÔ°ÄÃűÒ2ÍòÔªµÄ½òÌù£¬¼°Ã¿Ñ§Äê×î¶à°ÄÃűÒ1ÍòÔªµÄ»áÒé»òÑо¿»î¶¯½»Í¨½òÌù£¬ÎªÆÚ×ËÄÄê¡£
°Ä´ó婽­²©Ê¿Éú½±Ñ§½ðÏêÇéhttps://www.umac.mo/grs/cn/admissions_scholarship.php

°Ä´ó婽­²©Ê¿ºó½±Ñ§½ð
Á½Äê×ܽ±Ñ§½ð°ÄÃűÒ100Íò
1. Monthly remuneration of MOP40,000 (taxable).
2. Annual conference and research related trips allowance of MOP20,000.
3. Maximum contract period of 2 years*.
°Ä´ó婽­²©Ê¿ºó½±Ñ§½ðÏêÇéhttps://www.umac.mo/research/pag ... ication%202018.html

¸ßУ²©Ê¿ºóרÏî×ÊÖú¼Æ»®(°ÄÃÅ)
×ÊÖúÃû¶î: 50Ãû
ÿÔ½òÌù: 40,000.00 Mop (RMB35000)
×ÊÖúÆÚ£º×24¸öÔÂ
¸ßУ²©Ê¿ºóרÏî×ÊÖú¼Æ»®(°ÄÃÅ)ÏêÇé
http://www.fdct.gov.mo/zh_tw/postdoc.html

ÁªÏµ·½Ê½£º »¶Ó­Ö±½ÓÁªÏµ³ÂнÌÊÚ(Professor Xin Chen)£¨xchen@umac.mo£©¡£
ÉêÇ뷽ʽ£ºÍøÉϱ¨Ãû£¬¾ßÌ屨Ãû¼°ÕÐÉúÒªÇóÇë²ÎÔÄ°ÄÃÅ´óѧÑо¿ÉúÔºÍøÒ³£¨http://www.umac.mo/grs/cn/admissions.php£©

Selective recent publications (* corresponding or co-corresponding author):

1.He, T., S. Liu, S. Chen, J. Ye, X. Wu, Z. Bian and X. Chen (2018). "The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4+Foxp3+ Regulatory T Cells." Frontiers in Immunology 9(1556).

2.Zou, H., R. Li, H. Hu, Y. Hu and X. Chen (2018). "Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents." Frontiers in Immunology 9(594).

3.Nie, Y., J. He, H. Shirota, A. L. Trivett, Yang, D. M. Klinman, J. J. Oppenheim and X. Chen (2018). "Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer." Sci Signal 11(511).

4.Liu, S. and X. Chen (2018). "Dietary therapy may be sufficient for type 1 diabetes treatment." Cell Mol Immunol 15(2): 85-87.

5.Li, P., Y. Zheng and X. Chen (2017). "Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics." Front Pharmacol 8: 460.

6.Chen, X. and J. J. Oppenheim (2017). "Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer." Sci Signal 10(462).

7.Nie, Y., Yang, A. Trivett, Z. Han, H. Xin, X. Chen and J. J. Oppenheim (2017). "Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors." Sci Rep 7(1): 14186.

8.Chen, X. and J. J. Oppenheim (2016). "Therapy: Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity." Nat Rev Rheumatol 12(11): 625-626.

9.Zaragoza, B., X. Chen, J. J. Oppenheim, A. Baeyens, S. Gregoire, D. Chader, G. Gorochov, M. Miyara and B. L. Salomon (2016). "Suppressive activity of human regulatory T cells is maintained in the presence of TNF." Nat Med 22(1): 16-17.

10.Yan, F., R. Du, F. Wei, H. Zhao, J. Yu, C. Wang, Z. Zhan, T. Ding, X. Ren, X. Chen and H. Li (2015). "Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients." Cancer Immunol Immunother 64(11): 1475-1485.

11.Hamano, R., X. Wu, Y. Wang, J. J. Oppenheim and X. Chen (2015). "Characterization of MT-2 cells as a human regulatory T cell-like cell line." Cell Mol Immunol 12(6): 780-782.

12.Chen, X., J. Willette-Brown, X. Wu, Y. Hu, O. M. Howard, Y. Hu and J. J. Oppenheim (2015). "IKKalpha is required for the homeostasis of regulatory T cells and for the expansion of both regulatory and effector CD4 T cells." FASEB J 29(2): 443-454.


PIѧÊõ±³¾°£¬Çë²Î¼û£º
https://sklqrcm.umac.mo/xinchen/

°ÄÃÅ´óѧÐÂУÇø£¬Çë²Î¼û£º http://www.umac.mo/co/gallery.php#ad-image-0

·¢×ÔСľ³æAndroid¿Í»§¶Ë
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍƼö: (ÎÒÒ²ÒªÔÚÕâÀïÍƹã)

» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:

²é¿´È«²¿É¢½ðÌù

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

plyz061454

Òø³æ (СÓÐÃûÆø)


»¤ÀíÑо¿Éú²»ÖªµÀÄÜÉêÇë¶ÁÕâ¸ö·½Ïò²©Ê¿²»£¿

·¢×ÔСľ³æAndroid¿Í»§¶Ë
84Â¥2019-01-30 02:06:08
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 88 ¸ö»Ø´ð
¼òµ¥»Ø¸´
ÄÁÐÇ_2Â¥
2019-01-20 17:53   »Ø¸´  
chen36904311(½ð±Ò+2): лл²ÎÓë
ÒÑ»ñµÃ2¸ö½ð±Ò ·¢×ÔСľ³æIOS¿Í»§¶Ë
pandongzi3Â¥
2019-01-20 17:53   »Ø¸´  
chen36904311(½ð±Ò+2): лл²ÎÓë
ÒÑ»ñµÃ2¸ö½ð±Ò ·¢×ÔСľ³æIOS¿Í»§¶Ë
2019-01-20 17:53   »Ø¸´  
chen36904311(½ð±Ò+2): лл²ÎÓë
ÒÑ»ñµÃ2¸ö½ð±Ò ·¢×ÔСľ³æAndroid¿Í»§¶Ë
2019-01-20 17:54   »Ø¸´  
chen36904311(½ð±Ò+1): лл²ÎÓë
ÒÑ»ñµÃ1¸ö½ð±Ò ·¢×ÔСľ³æIOS¿Í»§¶Ë
2140248226Â¥
2019-01-20 17:54   »Ø¸´  
chen36904311(½ð±Ò+1): лл²ÎÓë
ÒÑ»ñµÃ1¸ö½ð±Ò ·¢×ÔСľ³æAndroid¿Í»§¶Ë
2019-01-20 17:54   »Ø¸´  
chen36904311(½ð±Ò+2): лл²ÎÓë
ÒÑ»ñµÃ2¸ö½ð±Ò ·¢×ÔСľ³æIOS¿Í»§¶Ë
Flyszer8Â¥
2019-01-20 17:54   »Ø¸´  
chen36904311(½ð±Ò+2): лл²ÎÓë
ÒÑ»ñµÃ2¸ö½ð±Ò ·¢×ÔСľ³æIOS¿Í»§¶Ë
2019-01-20 17:54   »Ø¸´  
chen36904311(½ð±Ò+1): лл²ÎÓë
ÒÑ»ñµÃ1¸ö½ð±Ò ·¢×ÔСľ³æAndroid¿Í»§¶Ë
tzynew10Â¥
2019-01-20 17:55   »Ø¸´  
chen36904311(½ð±Ò+2): лл²ÎÓë
ÒÑ»ñµÃ2¸ö½ð±Ò ·¢×ÔСľ³æAndroid¿Í»§¶Ë
ŶÁË11Â¥
2019-01-20 17:56   »Ø¸´  
chen36904311(½ð±Ò+1): лл²ÎÓë
ÒÑ»ñµÃ1¸ö½ð±Ò ·¢×ÔСľ³æAndroid¿Í»§¶Ë
goingggggg12Â¥
2019-01-20 17:56   »Ø¸´  
chen36904311(½ð±Ò+2): лл²ÎÓë
ÒÑ»ñµÃ2¸ö½ð±Ò ·¢×ÔСľ³æIOS¿Í»§¶Ë
2019-01-20 17:56   »Ø¸´  
chen36904311(½ð±Ò+1): лл²ÎÓë
ÒÑ»ñµÃ1¸ö½ð±Ò ·¢×ÔСľ³æAndroid¿Í»§¶Ë
wang810214Â¥
2019-01-20 17:56   »Ø¸´  
chen36904311(½ð±Ò+2): лл²ÎÓë
ÒÑ»ñµÃ2¸ö½ð±Ò ·¢×ÔСľ³æAndroid¿Í»§¶Ë
×î¾ßÈËÆøÈÈÌûÍƼö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[½Ìʦ֮¼Ò] Æß¼¶¸Ú£¬µ½ÊÖ²»µ½8000£¬´ø±¾¿ÆÂÛÎÄ12½Ìѧ·Ö/Éú£¬¶î¶¨½Ìѧ·Ö280 +4 ºÓÎ÷Ò¹ÀÉ 2024-05-02 4/200 2024-05-03 00:54 by 534720018
[¿¼²©] ±±¾©Ê¦·¶´óѧÈ˹¤ÖÇÄÜѧԺ2024ÄêµÚ¶þÅú²©Ê¿Ñо¿ÉúÕÐÉú±¨Ãû +3 taoto 2024-05-02 3/150 2024-05-02 21:45 by Bobby×ÔÐгµ
[ÂÛÎÄͶ¸å] Ͷ¸åRSCÆìÏÂÔÓ־ͻȻ¼ä¿´²»µ½Í¶¸å״̬£¬ÀïÃæͶ¸åµÄÎÄÕÂÐÅÏ¢²»¼ûÁË£¬ÓÐÓöµ½¹ýµÄÂ𣿠50+4 dlying 2024-04-26 5/250 2024-05-02 17:45 by aasahr
[˶²©¼ÒÔ°] ²©Ê¿ºóºÍ¿ÆÑÐÖúÀíºÃÄÑÕÒ°¡ +12 ÕÒ¹¤×÷°¡ 2024-04-28 12/600 2024-05-02 16:31 by xysxm
[»ù½ðÉêÇë] ¹ØÓÚ¹«²¼2024Äê¶È¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿ÉêÇë³õÉó½á¹ûµÄͨ¸æ +10 hdzw9071 2024-04-30 13/650 2024-05-02 14:44 by TY20221020
[»ù½ðÉêÇë] ¶à´óËã´óÁ䣿 +4 wyjecho666 2024-05-01 5/250 2024-05-02 13:47 by AD_com
[ÂÛÎÄͶ¸å] ÇóÖú£¬ÂÛÎÄСÐÞ·µÐÞÒÔºóScholarOneÉó¸åϵͳ ״̬ 20+5 15546226191 2024-04-30 9/450 2024-05-02 12:28 by ca0yan9
[¿¼²©] ²©Ê¿ÉêÇë +5 Farssh 2024-04-29 9/450 2024-05-02 10:39 by ѧÌ÷
[Óлú½»Á÷] DMFÔõô³ýË® +5 °®³ÔÏã²ËµÄС»Æ¹ 2024-05-01 10/500 2024-05-02 08:27 by kang1386
[»ù½ðÉêÇë] ½ñÄêÃæÉÏÔ¤¼ÆÓÖ´ò½´ÓÍÁË +13 speedxyl 2024-04-30 15/750 2024-05-02 06:37 by llhljsy
[²ÄÁÏ×ÛºÏ] ΪʲôʯīÑùµª»¯Ì¼»áÅijöÀ´Õâô¹îÒìµÄTEMÕÕƬ +4 Hikarico 2024-04-26 15/750 2024-05-01 17:38 by CQ_2021Z
[ÂÛÎÄͶ¸å] µÚһƪÂÛÎÄÖÕÓÚ½øÈ¥Éó¸å״̬ÁË +4 lizhengke06 2024-05-01 7/350 2024-05-01 17:16 by wjykycg
[¿¼²©] 2024»¹ÓÐûÓв¹Â¼µÄ²©Ê¿ +4 crazy peng 2024-04-30 5/250 2024-05-01 12:12 by crazy peng
[¿¼²©] »ªÄÏÀí¹¤´óѧδÀ´¼¼ÊõѧԺÁÖÕòºê½ÌÊÚ¡°ÄÜÔ´Óë̼¾ö²ß¡±¿ÎÌâ×éÕÐÊÕ2024¼¶²©Ê¿Éú +3 Áõ¼Òç²13 2024-04-28 3/150 2024-05-01 01:37 by ÃÎÏëÑо¿Éú
[¿¼²©] ÉêÇë25Ä격ʿ£¬ÇóÍƼöѧУ¼°²©µ¼ +4 Ã÷¿ªÒ¹ºÏ20 2024-04-28 7/350 2024-04-30 14:23 by Ã÷¿ªÒ¹ºÏ20
[ÕÒ¹¤×÷] ½­ËÕÀí¹¤Ñ§ÔºÒªÉ÷Ñ¡ +8 jjchenshui 2024-04-27 10/500 2024-04-30 10:29 by °ëÉúÃξý
[¸ß·Ö×Ó] Ë®ÐÔ¾Û°±õ¥ +4 ÄÆÓëË® 2024-04-28 6/300 2024-04-29 20:49 by qiyanjie1008
[ÂÛÎÄͶ¸å] ¹ØÓÚJournal of Crystal GrowthµÄOAºÍ°æÃæ·Ñ 50+4 ϯÑòÑò 2024-04-26 9/450 2024-04-28 22:17 by ϯÑòÑò
[Óлú½»Á÷] ï®ÑÎµÄºÏ³É 4+3 liurui1203 2024-04-27 3/150 2024-04-28 10:45 by 591950582
[½Ìʦ֮¼Ò] ´óѧֱÊôѧԺжÈεĸ±Ôº³¤ÍËÐݺó»¹ÏíÊܸ±´¦¼¶µÄÑøÀÏ´ýÓöÂ𣿠+6 ËÕ¶«Æ¶þÊÀ 2024-04-27 6/300 2024-04-28 08:35 by ou0551
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û